Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia.
Koschade SE, Klann K, Shaid S, Vick B, Stratmann JA, Thölken M, Meyer LM, Nguyen TD, Campe J, Moser LM, Hock S, Baker F, Meyer CT, Wempe F, Serve H, Ullrich E, Jeremias I, Münch C, Brandts CH. Koschade SE, et al. Among authors: moser lm. Leukemia. 2022 Oct;36(10):2396-2407. doi: 10.1038/s41375-022-01678-y. Epub 2022 Aug 23. Leukemia. 2022. PMID: 35999260 Free PMC article.
Correction: Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia.
Koschade SE, Klann K, Shaid S, Vick B, Stratmann JA, Thölken M, Meyer LM, Nguyen TD, Campe J, Moser LM, Hock S, Baker F, Meyer CT, Wempe F, Serve H, Ullrich E, Jeremias I, Münch C, Brandts CH. Koschade SE, et al. Among authors: moser lm. Leukemia. 2022 Dec;36(12):2950. doi: 10.1038/s41375-022-01721-y. Leukemia. 2022. PMID: 36347926 Free PMC article. No abstract available.
ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
Heim C, Moser LM, Kreyenberg H, Bonig HB, Tonn T, Wels WS, Gradhand E, Ullrich E, Meister MT, Koerkamp MG, Holstege FCP, Drost J, Klusmann JH, Bader P, Merker M, Rettinger E. Heim C, et al. Among authors: moser lm. Front Immunol. 2023 Aug 18;14:1228894. doi: 10.3389/fimmu.2023.1228894. eCollection 2023. Front Immunol. 2023. PMID: 37662907 Free PMC article.
Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation.
Heim C, Hartig L, Weinelt N, Moser LM, Salzmann-Manrique E, Merker M, Wels WS, Tonn T, Bader P, Klusmann JH, van Wijk SJL, Rettinger E. Heim C, et al. Among authors: moser lm. Mol Ther Oncol. 2024 Apr 11;32(2):200802. doi: 10.1016/j.omton.2024.200802. eCollection 2024 Jun 20. Mol Ther Oncol. 2024. PMID: 38706988 Free PMC article.
Donor-type red blood cell transfusion to deplete isoagglutinins prior to allogeneic stem cell transplantation from ABO major incompatible bone marrow donors.
Jarisch A, Salzmann-Manrique E, Soerensen J, Sach G, Rettinger E, Willasch A, Bakhtiar S, Klarmann D, Bräuninger S, Moser L, Fekadu J, Hutter M, Klingebiel T, Klusmann JH, Bader P, Bonig H. Jarisch A, et al. Br J Haematol. 2023 Jun;201(6):1159-1168. doi: 10.1111/bjh.18761. Epub 2023 Mar 22. Br J Haematol. 2023. PMID: 36949601
23 results